Search Results - "Leger, Kasey J"

Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children's Oncology Group by Getz, Kelly D, Sung, Lillian, Ky, Bonnie, Gerbing, Robert B, Leger, Kasey J, Leahy, Allison Barz, Sack, Leah, Woods, William G, Alonzo, Todd, Gamis, Alan, Aplenc, Richard

“…Late cardiotoxicity after pediatric acute myeloid leukemia therapy causes substantial morbidity and mortality. The impact of early-onset cardiotoxicity on…”
Get full text

Circulating microRNAs: Potential Markers of Cardiotoxicity in Children and Young Adults Treated With Anthracycline Chemotherapy by Leger, Kasey J, Leonard, David, Nielson, Danelle, de Lemos, James A, Mammen, Pradeep P A, Winick, Naomi J

“…Biomarkers for early detection of anthracycline (AC)-induced cardiotoxicity may allow cardioprotective intervention before irreversible damage. Circulating…”
Get full text

Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation by Leger, Kasey J., Baker, K. Scott, Cushing‐Haugen, Kara L., Flowers, Mary E. D., Leisenring, Wendy M., Martin, Paul J., Mendoza, Jason A., Reding, Kerryn W., Syrjala, Karen L., Lee, Stephanie J., Chow, Eric J.

“…BACKGROUND The objective of this study was to evaluate whether modifiable cardiovascular risk conditions and lifestyle factors were temporally associated with…”
Get full text

Building a machine learning-assisted echocardiography prediction tool for children at risk for cancer therapy-related cardiomyopathy by Edwards, Lindsay A, Yang, Christina, Sharma, Surbhi, Chen, Zih-Hua, Gorantla, Lahari, Joshi, Sanika A, Longhi, Nicolas J, Worku, Nahom, Yang, Jamie S, Martinez Di Pietro, Brandy, Armenian, Saro, Bhat, Aarti, Border, William, Buddhe, Sujatha, Blythe, Nancy, Stratton, Kayla, Leger, Kasey J, Leisenring, Wendy M, Meacham, Lillian R, Nathan, Paul C, Narasimhan, Shanti, Sachdeva, Ritu, Sadak, Karim, Chow, Eric J, Boyle, Patrick M

“…Despite routine echocardiographic surveillance for childhood cancer survivors, the ability to predict cardiomyopathy risk in individual patients is limited. We…”
Get full text

Longitudinal Changes in Echocardiographic Parameters of Cardiac Function in Pediatric Cancer Survivors by Border, William L., Sachdeva, Ritu, Stratton, Kayla L., Armenian, Saro H., Bhat, Aarti, Cox, David E., Leger, Kasey J., Leisenring, Wendy M., Meacham, Lillian R., Sadak, Karim T., Sivanandam, Shanthi, Nathan, Paul C., Chow, Eric J.

“…The purpose of this study was to assess the timing of changes in serial echocardiographic parameters in pediatric cancer survivors and to evaluate their…”
Get full text

Cardiotoxicity of CPX-351 in children and adolescents with relapsed AML: a Children's Oncology Group report by Leger, Kasey J, Absalon, Michael J, Demissei, Biniyam G, Smith, Amanda M, Gerbing, Robert B, Alonzo, Todd A, Narayan, Hari K, Hirsch, Betsy A, Pollard, Jessica A, Razzouk, Bassem I, Getz, Kelly D, Aplenc, Richard, Kolb, E Anders, Ky, Bonnie, Cooper, Todd M

“…Anthracyclines are effective in treating acute myeloid leukemia (AML) but limited by cardiotoxicity. CPX-351, a liposomal daunorubicin and cytarabine, may…”
Get full text

Rationale and design of the Children's Oncology Group study AAML1831 integrated cardiac substudies in pediatric acute myeloid leukemia therapy by Leger, Kasey J, Robison, Nora, Narayan, Hari K, Smith, Amanda M, Tsega, Tenaadam, Chung, Jade, Daniels, Amber, Chen, Zhen, Englefield, Virginia, Demissei, Biniyam G, Lefebvre, Benedicte, Morrow, Gemma, Dizon, Ilona, Gerbing, Robert B, Pabari, Reena, Getz, Kelly D, Aplenc, Richard, Pollard, Jessica A, Chow, Eric J, Tang, W H Wilson, Border, William L, Sachdeva, Ritu, Alonzo, Todd A, Kolb, E Anders, Cooper, Todd M, Ky, Bonnie

“…Pediatric acute myeloid leukemia (AML) therapy is associated with substantial short- and long-term treatment-related cardiotoxicity mainly due to high-dose…”
Get full text

Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy by Gardner, Rebecca A., Ceppi, Francesco, Rivers, Julie, Annesley, Colleen, Summers, Corinne, Taraseviciute, Agne, Gust, Juliane, Leger, Kasey J., Tarlock, Katherine, Cooper, Todd M., Finney, Olivia C., Brakke, Hannah, Li, Daniel H., Park, Julie R., Jensen, Michael C.

“…Immunotherapy with the adoptive transfer of T cells redirected with CD19-specific chimeric antigen receptors (CARs) for B-lineage acute lymphoblastic leukemia…”
Get full text

Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment by Chow, Eric J, Leger, Kasey J, Bhatt, Neel S, Mulrooney, Daniel A, Ross, Colin J, Aggarwal, Sanjeev, Bansal, Neha, Ehrhardt, Matthew J, Armenian, Saro H, Scott, Jessica M, Hong, Borah

“…Abstract With 5-year survival of children with cancer exceeding 80% in developed countries, premature cardiovascular disease is now a major cause of early…”
Get full text

Perforated jejunitis in a child with acute lymphoblastic leukemia treated with pegaspargase by Tang, Elizabeth R, Chapman, Teresa, Finn, Laura S, Leger, Kasey J

“…Survival rates of children with acute lymphoblastic leukemia have improved since the incorporation of asparaginase in the treatment protocol, but the…”
Get full text

Lack of benefit from premedication for pegylated asparaginase during pediatric acute lymphoblastic leukemia/lymphoma therapy: A side‐by‐side comparison by Menig, Sarah, Dinh, Andrew, Angus, Jonathan, Tucker, Sarah, Leger, Kasey J., Rushing, Teresa, Orgel, Etan

“…Background Pegylated l‐asparaginase (PEG) is integral to treatment regimens for acute lymphoblastic leukemia (ALL) and lymphoma. Hypersensitivity reactions…”
Get full text

Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults by Harker-Murray, Paul, Mauz-Körholz, Christine, Leblanc, Thierry, Mascarin, Maurizio, Michel, Gérard, Cooper, Stacy, Beishuizen, Auke, Leger, Kasey J., Amoroso, Loredana, Buffardi, Salvatore, Rigaud, Charlotte, Hoppe, Bradford S., Lisano, Julie, Francis, Stephen, Sacchi, Mariana, Cole, Peter D., Drachtman, Richard A., Kelly, Kara M., Daw, Stephen

“…•A risk-stratified, response-adapted salvage strategy resulted in high CMR rates with limited toxicities in CAYA with R/R cHL.•CMR rate after nivo + BV…”
Get full text

Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children's Oncology Group by Getz, Kelly D, Sung, Lillian, Alonzo, Todd A, Leger, Kasey J, Gerbing, Robert B, Pollard, Jessica A, Cooper, Todd, Kolb, E Anders, Gamis, Alan S, Ky, Bonnie, Aplenc, Richard

“…To determine whether dexrazoxane provides effective cardioprotection during frontline treatment of pediatric acute myeloid leukemia (AML) without increasing…”
Get full text

Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children's Oncology Group by Cooper, Todd M, Absalon, Michael J, Alonzo, Todd A, Gerbing, Robert B, Leger, Kasey J, Hirsch, Betsy A, Pollard, Jessica, Razzouk, Bassem I, Aplenc, Richard, Kolb, E Anders

“…Effective regimens are needed for children with relapsed acute myeloid leukemia (AML). AAML1421 is a phase I/II study of CPX-351, a liposomal preparation of…”
Get full text

Minimizing cardiac toxicity in children with acute myeloid leukemia by Narayan, Hari K, Getz, Kelly D, Leger, Kasey J

“…Anthracycline chemotherapy remains an integral component of modern pediatric acute myeloid leukemia (AML) regimens and is often delivered at high doses to…”
Get full text

Multimodality Imaging for Cardiac Surveillance of Cancer Treatment in Children: Recommendations From the American Society of Echocardiography by Mertens, Luc, Singh, Gautam, Armenian, Saro, Chen, Ming-Hui, Dorfman, Adam L, Garg, Ruchira, Husain, Nazia, Joshi, Vijaya, Leger, Kasey J, Lipshultz, Steven E, Lopez-Mattei, Juan, Narayan, Hari K, Parthiban, Anitha, Pignatelli, Ricardo H, Toro-Salazar, Olga, Wasserman, Melissa, Wheatley, Jacqueline

Get full text

Future Perspectives of Cardiovascular Biomarker Utilization in Cancer Survivors: A Scientific Statement From the American Heart Association by Zaha, Vlad G., Hayek, Salim S., Alexander, Kevin M., Beckie, Theresa M., Hundley, W. Gregory, Kondapalli, Lavanya, Ky, Bonnie, Leger, Kasey J., Meijers, Wouter C., Moslehi, Javid J., Shah, Svati H.

“…Improving cancer survival represents the most significant effect of precision medicine and personalized molecular and immunologic therapeutics. Cardiovascular…”
Get full text

Progress Toward Cardiac Risk Reduction With the Evolution of Pediatric Hodgkin Lymphoma Therapy by Leger, Kasey J, Narayan, Hari K

Get full text

Late effects in high‐risk neuroblastoma survivors treated with high‐dose chemotherapy and stem cell rescue by Elzembely, Mahmoud M., Dahlberg, Ann E., Pinto, Navin, Leger, Kasey J., Chow, Eric J., Park, Julie R., Carpenter, Paul A., Baker, K. Scott

“…Background Current treatment strategies have improved the outcome of high‐risk neuroblastoma (HRNB) at the cost of increasing acute and late effects of…”
Get full text

Predicting Left Ventricular Dysfunction in Childhood Cancer Survivors: In Search of the Echocardiography Holy Grail by Border, William L, Effinger, Karen E, Leger, Kasey J

Get full text